Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

Abstract: The present disclosure provides a self-ligating bracket, a double-wing spacing adjustable bracket and a dental appliance. The self-ligating bracket includes: a bracket base plate; a first end of a first elastic support is connected to the bracket base plate; a bracket body is a hollow structure, a second end of the first elastic support is connected to a distal end of the bracket body, and the distal end of the bracket body is provided with a gap and the distal end of the bracket body is expanded radially by the second end of the first elastic support; and a position-limited member is movable in an axial direction of the bracket body, and the position-limited member is sleeved on an outside of the bracket body for overcoming expansive force provided by the elastic supports and making the bracket body contract along a radial direction.

Abstract: Methods of inhibiting platelet activation and aggregation using antibodies or peptide vaccines having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.

Abstract: Methods of preventing and treating type-1 diabetes and its complications using peptide vaccines to generate endogenous specific antibody activators that bind to the (Na++K+)-ATPase.

Abstract: Methods of preventing and treating type-1 diabetes and its complications using antibody activators that bind to the (Na++K+)-ATPase.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQWTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: Methods of preventing and treating PKD and its complications using antibody activators that bind to the (Na++K+)-ATPase.

Abstract: Methods of preventing and treating type-1 diabetes and its complications using antibody activators that bind to the (Na++K+)-ATPase.

Abstract: Methods of inhibiting platelet activation and aggregation using antibodies or peptide vaccines having binding specificity for the a subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.

Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of increasing NKA activity and cardiac contraction through administration of the peptide vaccines or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQWTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of increasing NKA activity and cardiac contraction through administration of the peptide vaccines or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1(?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of increasing NKA activity and cardiac contraction through administration of the peptide vaccines or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccine or antibodies that have binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such peptide vaccine or antibodies.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of increasing NKA activity and cardiac contraction through administration of the peptide vaccines or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of agonizing NKA activity through administration of the peptides or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccine or antibodies that have binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such peptide vaccine or antibodies.

Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such antibodies.